$123 Million is the total value of Nan Fung Group Holdings Ltd's 39 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 14.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | KARUNA THERAPEUTICS INC | $38,161,584 | -22.0% | 225,688 | 0.0% | 30.90% | -1.2% | |
| ILMN | ILLUMINA INC | $16,363,227 | -26.8% | 119,196 | 0.0% | 13.25% | -7.2% | |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $12,081,152 | -6.9% | 368,665 | 0.0% | 9.78% | +18.0% | |
| SGEN | SEAGEN INC | $9,991,416 | +10.2% | 47,096 | 0.0% | 8.09% | +39.7% | |
| Sell | OCULIS HOLDING AGordinary shares | $6,673,524 | -16.9% | 606,684 | -6.8% | 5.40% | +5.3% | |
| SOMALOGIC INC | $4,054,774 | +3.5% | 1,696,558 | 0.0% | 3.28% | +31.1% | ||
| EXSCIENTIA PLCads | $3,886,712 | -23.6% | 859,892 | 0.0% | 3.15% | -3.3% | ||
| XENE | Sell | XENON PHARMACEUTICALS INC | $3,644,189 | -17.2% | 106,680 | -6.7% | 2.95% | +4.9% |
| MRUS | Sell | MERUS N V | $3,231,356 | -18.7% | 137,038 | -9.2% | 2.62% | +3.0% |
| REPL | REPLIMUNE GROUP INC | $3,160,884 | -26.3% | 184,739 | 0.0% | 2.56% | -6.6% | |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $2,258,938 | +22.6% | 234,573 | +14.6% | 1.83% | +55.3% |
| BGNE | BEIGENE LTDsponsored adr | $2,162,397 | +0.9% | 12,022 | 0.0% | 1.75% | +27.8% | |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $2,087,106 | – | 182,280 | +100.0% | 1.69% | – |
| INCY | INCYTE CORP | $1,849,911 | -7.2% | 32,022 | 0.0% | 1.50% | +17.6% | |
| GERN | Buy | GERON CORP | $1,597,526 | +28.3% | 753,550 | +94.2% | 1.29% | +62.6% |
| EXEL | EXELIXIS INC | $1,402,770 | +14.3% | 64,200 | 0.0% | 1.14% | +44.9% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $1,213,630 | -18.8% | 1,166,952 | 0.0% | 0.98% | +2.9% | |
| PACB | PACIFIC BIOSCIENCES CALIF IN | $1,141,069 | -37.2% | 136,655 | 0.0% | 0.92% | -20.5% | |
| RANI THERAPEUTICS HLDGS INC | $1,073,545 | -47.2% | 493,584 | 0.0% | 0.87% | -33.2% | ||
| RYTM | RHYTHM PHARMACEUTICALS INC | $918,605 | +39.0% | 40,070 | 0.0% | 0.74% | +76.3% | |
| ENTRADA THERAPEUTICS INC | $775,496 | +4.4% | 49,082 | 0.0% | 0.63% | +32.2% | ||
| CABA | Buy | CABALETTA BIO INC | $717,623 | +35.2% | 47,150 | +14.7% | 0.58% | +71.4% |
| ARGX | ARGENX SEsponsored adr | $703,031 | +26.1% | 1,430 | 0.0% | 0.57% | +59.8% | |
| AVTE | AEROVATE THERAPEUTICS INC | $650,492 | -20.9% | 47,936 | 0.0% | 0.53% | +0.4% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $624,867 | -13.0% | 29,984 | 0.0% | 0.51% | +10.2% | |
| BMEA | BIOMEA FUSION INC | $550,400 | -37.3% | 40,000 | 0.0% | 0.45% | -20.5% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $504,492 | -28.4% | 370,950 | 0.0% | 0.41% | -9.1% | |
| ATHA | Buy | ATHIRA PHARMA INC | $363,600 | +947.3% | 180,000 | +1429.4% | 0.29% | +1236.4% |
| EARGO INC | $321,100 | -56.0% | 147,904 | 0.0% | 0.26% | -44.2% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $319,855 | +2.1% | 3,615 | 0.0% | 0.26% | +29.5% | |
| AKRO | AKERO THERAPEUTICS INC | $223,817 | +8.3% | 4,425 | 0.0% | 0.18% | +37.1% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $201,360 | -36.1% | 41,950 | 0.0% | 0.16% | -18.9% | |
| AFMD | AFFIMED N V | $178,004 | -20.1% | 372,472 | 0.0% | 0.14% | +1.4% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $126,357 | +0.6% | 17,847 | 0.0% | 0.10% | +27.5% | |
| GRTX | GALERA THERAPEUTICS INC | $107,375 | -94.4% | 613,223 | 0.0% | 0.09% | -92.9% | |
| ABCL | ABCELLERA BIOLOGICS INC | $57,597 | -28.8% | 12,521 | 0.0% | 0.05% | -9.6% | |
| FGEN | FIBROGEN INC | $53,591 | -68.0% | 62,106 | 0.0% | 0.04% | -59.8% | |
| KOD | KODIAK SCIENCES INC | $35,320 | -73.9% | 19,622 | 0.0% | 0.03% | -66.7% | |
| CERS | CERUS CORP | $22,959 | -34.1% | 14,172 | 0.0% | 0.02% | -13.6% | |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -1,182 | -100.0% | -0.18% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -3,300 | -100.0% | -0.22% | – |
| Exit | GITLAB INC | $0 | – | -6,910 | -100.0% | -0.23% | – | |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -113,950 | -100.0% | -2.80% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -111,984 | -100.0% | -2.82% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.